Finanzen von Adagio Medical Holdings Inc (ADGM)ADGMAdagio Medical Holdings Inc

Evaluating the bottom line, Adagio Medical Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -657.76%, provide a clear picture of how effectively ADGM converts its operational activities into shareholder value.

In the context of the broader market, ADGM competes directly with industry leaders such as NXL and VBIO. With a market capitalization of $2.83M, it holds a significant position in the sector. When comparing efficiency, ADGM's gross margin of N/A stands against NXL's 73.16% and VBIO's N/A. Such benchmarking helps identify whether Adagio Medical Holdings Inc is trading at a premium or discount relative to its financial performance.

Adagio Medical has reported a net loss of $7.0 million for Q1 2026, down from $7.7 million in Q1 2025, indicating some improvement but still significant losses. The gross margin is negative at -1011.68% for Q4 2024, and the company has not generated revenue in recent quarters, raising concerns about its viability.